Premier Pharma 1 LP
Premier Pharma 1 LP is a private investment fund based in New York, New York. Its most recent Form D, filed Dec 7, 2016, reports no sales yet. The minimum investment it accepts from an outside investor is $500,000. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Michael Korn; Morgan Stanley Strategies II LLC; Jeremy Beal.
- Total raised
- $0Cumulative sales reported on Form D
- Investors
- 0
- First sale
- —
- Minimum investment
- $500,000
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Michael Korn; Morgan Stanley Strategies II LLC; Jeremy Beal
- Latest Form D
- Dec 7, 2016
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about Premier Pharma 1 LP
What is the minimum investment for Premier Pharma 1 LP?
According to its latest Form D, filed Dec 7, 2016, the minimum investment Premier Pharma 1 LP accepts from an outside investor is $500,000.
Who can invest in Premier Pharma 1 LP?
Premier Pharma 1 LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Premier Pharma 1 LP raised?
Premier Pharma 1 LP's latest Form D, filed Dec 7, 2016, reports no sales yet.
Where is Premier Pharma 1 LP based?
Premier Pharma 1 LP is based in New York, New York.
Size compared with every private investment fund
This fund hasn't reported any sales yet.